FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304321> ?p ?o ?g. }

• W4367304321 abstract "<h3>Objective:</h3> The study aims to confirm the efficacy and safety of erenumab in migraine patients. <h3>Background:</h3> Migraine prevention with erenumab is approved in Kuwait. It is a fully human monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr). <h3>Design/Methods:</h3> This is a prospective, real-life, cohort study. In our tertiary hospital in Kuwait, we selected patients with a ICHD-3 diagnosis of migraine who received erenumab monthly between May 2019 and April 2022. The study included migraine patients aged 18 to 65 years treated with erenumab in the Headache clinic. Primary endpoint of this analysis was the mean change in monthly headache days from the baseline until the end of observational period. Secondary endpoints were changes days with acute headache medication in the treatment period, severity of headache pain and change of quality of after treatment. <h3>Results:</h3> A total of 151 migraine patients were identified to the study, 123 (81.5%) were female, with a mean age of 20.23±11.74 years. Erenumab decreased mean headache days frequency from 15.05 ± 8.93 to 6.08± 6.05; p<0.002; mean monthly days of analgesic use from 15.48 ±8.77 to 6.30± 6.83; P < 0.001), and mean severity of headache pain from 8.75± 1.67 to 5.46 ±2.90. Constipation (6%) was the most frequent adverse events reported. <h3>Conclusions:</h3> At the end of study, we reported a statistically significant reduction in the mean number of monthly headache days, acute medication use per month, and improvement of quality of life. Results of this real-world setting are comparable to results of clinical trials. <b>Disclosure:</b> Dr. Alshawaf has nothing to disclose. Dr. Ahmed has nothing to disclose. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Bayer, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen, Novartis, Merck, Roche, Sanofi. Dr. Al-Hashel has nothing to disclose." @default.
• W4367304321 created "2023-04-29" @default.
• W4367304321 creator A5000026859 @default.
• W4367304321 creator A5049456235 @default.
• W4367304321 creator A5062413415 @default.
• W4367304321 creator A5065095387 @default.
• W4367304321 date "2023-04-25" @default.
• W4367304321 modified "2023-09-25" @default.
• W4367304321 title "Real-Life Experience with Erenumab Therapy in the Episodic and Chronic Migraine. (P12-12.004)" @default.
• W4367304321 doi "https://doi.org/10.1212/wnl.0000000000202772" @default.
• W4367304321 hasPublicationYear "2023" @default.
• W4367304321 type Work @default.
• W4367304321 citedByCount "0" @default.
• W4367304321 crossrefType "proceedings-article" @default.
• W4367304321 hasAuthorship W4367304321A5000026859 @default.
• W4367304321 hasAuthorship W4367304321A5049456235 @default.
• W4367304321 hasAuthorship W4367304321A5062413415 @default.
• W4367304321 hasAuthorship W4367304321A5065095387 @default.
• W4367304321 hasConcept C126322002 @default.
• W4367304321 hasConcept C159110408 @default.
• W4367304321 hasConcept C187212893 @default.
• W4367304321 hasConcept C197934379 @default.
• W4367304321 hasConcept C203092338 @default.
• W4367304321 hasConcept C23131810 @default.
• W4367304321 hasConcept C2778541695 @default.
• W4367304321 hasConcept C2779951463 @default.
• W4367304321 hasConcept C2781112942 @default.
• W4367304321 hasConcept C2910587157 @default.
• W4367304321 hasConcept C535046627 @default.
• W4367304321 hasConcept C71924100 @default.
• W4367304321 hasConceptScore W4367304321C126322002 @default.
• W4367304321 hasConceptScore W4367304321C159110408 @default.
• W4367304321 hasConceptScore W4367304321C187212893 @default.
• W4367304321 hasConceptScore W4367304321C197934379 @default.
• W4367304321 hasConceptScore W4367304321C203092338 @default.
• W4367304321 hasConceptScore W4367304321C23131810 @default.
• W4367304321 hasConceptScore W4367304321C2778541695 @default.
• W4367304321 hasConceptScore W4367304321C2779951463 @default.
• W4367304321 hasConceptScore W4367304321C2781112942 @default.
• W4367304321 hasConceptScore W4367304321C2910587157 @default.
• W4367304321 hasConceptScore W4367304321C535046627 @default.
• W4367304321 hasConceptScore W4367304321C71924100 @default.
• W4367304321 hasLocation W43673043211 @default.
• W4367304321 hasOpenAccess W4367304321 @default.
• W4367304321 hasPrimaryLocation W43673043211 @default.
• W4367304321 hasRelatedWork W2115510535 @default.
• W4367304321 hasRelatedWork W2781760325 @default.
• W4367304321 hasRelatedWork W2805181790 @default.
• W4367304321 hasRelatedWork W3015052705 @default.
• W4367304321 hasRelatedWork W3015626321 @default.
• W4367304321 hasRelatedWork W3162538154 @default.
• W4367304321 hasRelatedWork W4254363211 @default.
• W4367304321 hasRelatedWork W4290096750 @default.
• W4367304321 hasRelatedWork W4324147070 @default.
• W4367304321 hasRelatedWork W4367053521 @default.
• W4367304321 isParatext "false" @default.
• W4367304321 isRetracted "false" @default.
• W4367304321 workType "article" @default.